DBV Technologies to Participate in Upcoming ACAAI Congress
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, is excited to announce its participation in the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting this year. The meeting will take place from October 24 to 28, bringing together professionals from the field to discuss advancements and challenges in allergy treatment.
Highlight of the Meeting: The Product Theater
One of the focal points of the ACAAI meeting will be a “Product Theater” titled What Defines an Optimal Peanut Allergy Treatment? This panel will host leading experts including Drs. Shahzad Mustafa, Edwin Kim, Julia Upton, and Eleanor Garrow-Holding, CEO of Food Allergy and Anaphylaxis Connection Team (FAACT). They will exchange insights on creating effective peanut allergy treatments, with a session scheduled for Saturday, October 26, from 11:35 a.m. to 1:00 p.m. EDT.
Supporting the Allergy Community
DBV Technologies will also sponsor the 33rd Annual FIT Bowl, an engaging competition that tests the knowledge of allergy, asthma, and immunology among teams from various training programs. This event will take place on Saturday, October 26, from 5:45 p.m. to 7:45 p.m. EDT. Additionally, DBV is proud to be a Benefactor Level Corporate Council Member at the ACAAI 2024, reinforcing its dedication to advancing allergy care.
DBV Presentation at the ACAAI Meeting
Presenting at Product Theater:
DBV Technologies will play a significant role in discussing optimal treatment for peanut allergies. The company's presentation will provide critical insights into the challenges faced by those with this condition, enabling a deeper understanding of therapeutic approaches.
Details of the Presentation
- Presentation Date: Saturday, October 26
- Presentation Time: 11:35 a.m. to 1:00 p.m. EDT
- Session/location: HCC, Level 2, Exhibit Halls C & D, Product Theater #2
At the core of DBV's presentation will be the innovative Viaskin® Peanut patch, developed to help manage allergic reactions triggered by peanuts. This investigational patch delivers specific quantities of peanut protein through the skin, aiming to retrain the immune system.
About DBV Technologies
DBV Technologies stands at the forefront of developing biopharmaceutical solutions for food allergies and immunologic disorders. Recognizing that millions of individuals, particularly children, wrestle with food allergies daily, DBV is committed to deciphering the intricate nature of these conditions. The company is currently engaged in clinical trials assessing the Viaskin® Peanut patch, hoping to deliver a much-needed solution for young peanut allergy sufferers—ages 1 to 7.
The Viaskin® Peanut patch represents a significant innovation in allergy treatment, employing epicutaneous immunotherapy (EPIT™) to help desensitize individuals to allergens via their skin. Through this technique, DBV aims to change how allergic reactions are treated, moving away from traditional methods toward a more modern, personal approach to care.
Headquartered in Châtillon, France, with a strong operational presence in North America, DBV Technologies is dedicated to pioneering change in food allergy management. The company's ordinary shares are traded on Euronext Paris under the ticker symbol DBV, while its American Depository Shares (ADS), representing ordinary shares, trade on Nasdaq under the ticker DBVT.
For those interested in learning more about DBV Technologies and its impactful work, additional information is available through their official website and their active presence on social media platforms such as X (formerly Twitter) and LinkedIn.
Frequently Asked Questions
1. What is the main focus of DBV Technologies?
DBV Technologies focuses on developing treatments for food allergies, specifically using their innovative Viaskin patch technology.
2. When is the ACAAI Annual Scientific Meeting taking place?
The ACAAI Annual Scientific Meeting will occur from October 24 to 28.
3. Who are the experts presenting in the Product Theater?
The panel includes Drs. Shahzad Mustafa, Edwin Kim, Julia Upton, and Eleanor Garrow-Holding.
4. What is the purpose of the Viaskin® Peanut patch?
The Viaskin Peanut patch aims to provide a non-invasive method to reduce the risk of allergic reactions to peanuts.
5. Where can I find more information about DBV Technologies?
Additional information can be found on the DBV Technologies official website and their social media channels.
